Announced Thu, 2 Jul · 10:36 IST
Aurobindo Pharma completes transfer of domestic branded formulations business to subsidiary
Strategic Transactions View source PDF
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.3%1-day move
₹1550.10
prior close
₹1554.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.1-0.3-0.1+4.3+2.9+2.1+0.5+2.1-0.1-1.6———
Up moveDown movePending
AI summary
Aurobindo Pharma has completed the transfer of its domestic branded generic pharmaceutical formulations business to Auropharm Limited, its wholly owned subsidiary, on a slump sale basis. The business transfer agreement was signed on April 6, 2026, and the transfer is effective from July 1, 2026. Auropharm was formerly known as Auro Pharma Limited.
Likely market impact
Internal restructuring to wholly owned subsidiary. Ownership unchanged. Watch for updates on subsidiary performance.